The FDA on March 4, 2015 granted approval to OPDIVO® for the treatment of patients with metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) with progression on or after platinum-based chemotherapy. OPDIVO® was previously approved in December, 2014 for the treatment of patients with unresectable or metastatic melanoma and disease progression following YERVOY® (Ipilimumab) and if BRAF V600 mutation positive, a BRAF inhibitor. OPDIVO® is a product of Bristol-Myers Squibb Company.
Other Pages – Bottom Ad
Advertisement
Subscribe
